Spark Therapeutics

Express Scripts staking out million-dollar gene therapies
Express Scripts staking out million-dollar gene therapies
Reuters
Express Scripts
PBMs
gene therapies
drug pricing
Biomarin
Bluebird Bio
Spark Therapeutics
Flag link:
What's Next for Spark Therapeutics
What's Next for Spark Therapeutics
Motley Fool
Spark Therapeutics
hemophilia
SPK-8011
Flag link:
3 Beaten-Down Biotech Stocks: Can They Recover?
3 Beaten-Down Biotech Stocks: Can They Recover?
Motley Fool
Idera
Spark Therapeutics
Tesaro
Flag link:
7 companies to watch during Q2 earnings
7 companies to watch during Q2 earnings
Biopharma Dive
earnings
Biogen
Gilead Sciences
Amgen
Celgene
AbbVie
Pfizer
Spark Therapeutics
Flag link:
3 Biotech Stocks With Major Catalysts Incoming
3 Biotech Stocks With Major Catalysts Incoming
Motley Fool
Spark Therapeutics
Zogenix
Progenics Pharmaceuticals
SPK-8011
ZX008
Azedra
FDA
Flag link:
Is biopharma’s first $1.5M therapy now in Phase III?
Is biopharma’s first $1.5M therapy now in Phase III?
Endpoints
drug pricing
gene therapy
Luxturna
Spark Therapeutics
Flag link:
Sparks sells regulatory fast pass to Jazz for $110M
Sparks sells regulatory fast pass to Jazz for $110M
Biopharma Dive
Spark Therapeutics
Jazz Pharmaceuticals
priority review vouchers
Flag link:
‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price
‘That’s $425,000 right there’ — the anxious launch of a gene therapy with a record sticker price
Stat
gene therapy
drug pricing
drug launches
Luxturna
Spark Therapeutics
Flag link:
Spark lays groundwork for US Luxturna launch
Spark lays groundwork for US Luxturna launch
Biopharma Dive
Spark Therapeutics
Luxturna
drug launches
gene therapy
Flag link:
Cost over sight? Spark's blindness cure has the industry talking
Cost over sight? Spark's blindness cure has the industry talking
Medical Marketing and Media
Spark Therapeutics
drug pricing
Luxturna
Flag link:
Novartis move signals further gene therapy resurgence
Novartis move signals further gene therapy resurgence
EP Vantage
Novartis
gene therapy
Spark Therapeutics
CAR-T
Luxturna
Flag link:
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Yahoo/Reuters
Spark Therapeutics
Novartis
Luxturna
gene therapy
Flag link:
Three Interviews From the J.P. Morgan Healthcare Conference
Three Interviews From the J.P. Morgan Healthcare Conference
Motley Fool
JPMHC 2018
Alnylam
Arena Pharmaceuticals
Spark Therapeutics
Flag link:
Drugmakers see a pricing blueprint in an $850,000 gene therapy
Drugmakers see a pricing blueprint in an $850,000 gene therapy
Reuters
gene therapy
drug pricing
Spark Therapeutics
Luxturna
Flag link:
Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns
Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns
Stat
Spark Therapeutics
gene therapy
Luxturna
drug pricing
rebates
Flag link:
FDA rolls out an early and historic OK for Spark’s pioneering gene therapy
FDA rolls out an early and historic OK for Spark’s pioneering gene therapy
Endpoints
FDA
Spark Therapeutics
gene therapy
Luxturna
retinal dystrophies
Flag link:
8 Takeout targets to watch in 2018
8 Takeout targets to watch in 2018
BioPharma Dive
M&A
Allergan
Alnylam
Biomarin
Bristol-Myers Squibb
Incyte
Madrigal Pharmaceuticals
Spark Therapeutics
Sucampo
Flag link:
[video]ASH 2017 Recap: These Were the Big Winners and Losers
[video]ASH 2017 Recap: These Were the Big Winners and Losers
Motley Fool
ASH2017
Bluebird Bio
Juno Therapeutics
Spark Therapeutics
Biomarin
JNJ
Celgene
Flag link:
ASH 2017: What you missed
ASH 2017: What you missed
BioPharma Dive
ASH17
Biomarin
Spark Therapeutics
Gilead Sciences
Novartis
Juno Therapeutics
AbbVie
Roche
JNJ
Flag link:
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
ASH17: Spark gene therapy falls behind BioMarin in hemophilia
BioPharma Dive
ASH17
Spark Therapeutics
gene therapy
Biomarin
hemophilia A
SPK-8011
Flag link:

Pages